Moleculin terminates $50M ATM equity agreement with Oppenheimer; no shares ever sold

Moleculin Biotech, Inc.

Delivered termination notice to Oppenheimer on Feb 3, 2023; effective Feb 13, 2023.
ATM agreement dated June 25, 2021 allowed up to $50M in common stock sales.
No shares were sold under the ATM agreement during its entire term.
Termination was at-will and without penalty per Section 13(b) of the agreement.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Moleculin Biotech, Inc. terminated At Market Issuance Sales Agreement with Oppenheimer & Co. Inc. valued at up to $50,000,000 (effective 2023-02-03).

Action: termination
Agreement: atm program
Counterparty: Oppenheimer & Co. Inc.
Value: up to $50,000,000
Effective: 2023-02-03

Exact text from the filing

On February 3, 2023, Moleculin Biotech, Inc. (“Company”) delivered written notice to Oppenheimer & Co. Inc. (the “Agent”) that it was terminating its At Market Issuance Sales Agreement, dated June 25, 2021 (the “ATM Agreement”), pursuant to Section 13(b) of the ATM Agreement, effective on February 13, 2023.

View on SEC.gov

115 material agreements filed in the last 30 days. Browse all material agreements →

Moleculin Biotech, Inc. filing history →

Source: SEC EDGAR

accession 0001437749-23-002493

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.